CoChat

The PD‐1 Interactome

Open access

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Abstract

T cell activation is a fine-tuned process that involves T cell receptor and costimulation signals. To prevent undue activation of T cells, inhibitory molecules including PD-1 (programmed death 1) are induced and function as brakes for T cell signaling. In a steady state, the interaction of PD-1 with its ligands PD-L1 (B7-H1, CD274) and PD-L2 (B7-DC, CD273) maintains peripheral immune tolerance. However, the expression of PD-L1 on tumor cells and interaction with PD-1 on T cells dampen anti-tumor immunity. Therapeutic inhibitors of the PD-1 pathway have revolutionized tumor immunotherapy. Unfortunately, the majority of patients do not develop sustained anti-tumor responses. However, the knowledge about unique PD-1 interactions and their role in mediating PD-1 inhibitory signals is currently limited. Advances in the mechanistic understanding of the molecular and signaling integration of the PD-1 pathway could unleash the great potential in tumor immunotherapy by allowing the development of combinatorial approaches that target not only PD-1 and its ligands but also its unique downstream signal mediators. In this review, the current advances in understanding the mechanisms of extracellular and intracellular PD-1 interactions and their significance in potential future therapeutic approaches are discussed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/adbi.202100758

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Interaction network of PD-1 with its ligands. A) The classic trans interaction of PD-1 on T cells and PD-L1 on APC reduces T cells activation via inhibition of TCR and CD28 signaling (left panel). PD-1 is also expressed on innate immune cells, in which the cis interaction of PD-1/PD-L1 might result in less free PD-L1 to bind PD-1 on T cells, thus prevent PD-1 inhibitory signaling on T cells (middle panel). As PD-L1 is also expressed on T cells and is further upregulated after T cell activation, the cis interaction of PD-1/PD-L1 might take place on T cells after T cell activation (right panel). This cis interaction of PD-1/PD-L1 and self-inhibition on T cells might prevent a continuous activation state. B) PD-L1 is highly expressed on T cells, thus the bidirectional signal of PD-L1 may change the functional fate of T cells in the tumor microenvironment. In this setting, PD-1 might act as a ligand for PD-L1 and transmit an inhibitory signal to T cells and macrophages in the tumor tissue. The backward singling of PD-L1 might shift CD4+ T cells from Th1 to Th17 and limit cytotoxic effects of CD8+ T cells in the tumor. The forward signaling of PD-L1 changes inflammatory macrophages (M1) to pro-tumor (M2) macrophages. In addition, forward signaling of PD-L1 via PD-1 can reduce production of inflammatory cytokines and effector cytotoxic T lymphocytes (CTL). Overall, the bidirectionality of PD-L1 signaling dampens immune responses against tumor. GzmB, Granzyme B. C) T cell activation requires a first signal from the TCR and second co-stimulatory signal from CD28 (CD28/B7–1). To counteract this process, inhibitory signals from CTLA-4 (CTLA-4/B7–1) and PD-1 (PD-1/PD-L1) act as brakes for further activation of T cells. CTLA-4 mediates its inhibitory function via endocytosis after binding with its ligand B7–1. The trans interaction of PD-L1 and B7–1 was previously reported to inhibit T cell activation. D) The cis interaction of PD-L1 and B7–1 on both APC and T cells. In co-culture of T cell and APC, the cis interaction of PD-L1 and B7–1 blocks the trans interaction of PD-L1/PD-1, thus making PD-L1 less available on APC for binding PD-1 on T cells, resulting in improved T cell activation. However, this relies on more expression of B7–1 than PD-L1 on APC cells. Interestingly, the cis interaction of PD-L1/B7–1 has no effects on the trans B7–1 binding to CTLA-4 and CD28. E) When PD-L1 outnumbers B7–1 on APC cells, the cis interaction of PD-L1 and B7–1 might have limited effects on trans interaction of PD-L1/PD-1. The excess of PD-L1 on APC could still bind to PD-1 and transmit inhibitory signals to T cells. F) When PD-L1 outnumbers B7–1 on APC cells, blocking cis interaction of PD-L1/B7–1 and trans interaction of PD-L1/PD-1 by anti-PD-L1 can further activate T cells. However, in this case, the released B7–1 on APC might bind to CTLA-4 on T cells and cause their inhibition. Thus, combination of anti-PD-L1 and anti-CTLA-4 under these conditions could maximize T cell activation and may be an efficient approach to improve tumor immunotherapy.
Figure 1. Interaction network of PD-1 with its ligands. A) The classic trans interaction of PD-1 on T cells and PD-L1 on APC reduces T cells activation via inhibition of TCR and CD28 signaling (left panel). PD-1 is also expressed on innate immune cells, in which the cis interaction of PD-1/PD-L1 might result in less free PD-L1 to bind PD-1 on T cells, thus prevent PD-1 inhibitory signaling on T cells (middle panel). As PD-L1 is also expressed on T cells and is further upregulated after T cell activation, the cis interaction of PD-1/PD-L1 might take place on T cells after T cell activation (right panel). This cis interaction of PD-1/PD-L1 and self-inhibition on T cells might prevent a continuous activation state. B) PD-L1 is highly expressed on T cells, thus the bidirectional signal of PD-L1 may change the functional fate of T cells in the tumor microenvironment. In this setting, PD-1 might act as a ligand for PD-L1 and transmit an inhibitory signal to T cells and macrophages in the tumor tissue. The backward singling of PD-L1 might shift CD4+ T cells from Th1 to Th17 and limit cytotoxic effects of CD8+ T cells in the tumor. The forward signaling of PD-L1 changes inflammatory macrophages (M1) to pro-tumor (M2) macrophages. In addition, forward signaling of PD-L1 via PD-1 can reduce production of inflammatory cytokines and effector cytotoxic T lymphocytes (CTL). Overall, the bidirectionality of PD-L1 signaling dampens immune responses against tumor. GzmB, Granzyme B. C) T cell activation requires a first signal from the TCR and second co-stimulatory signal from CD28 (CD28/B7–1). To counteract this process, inhibitory signals from CTLA-4 (CTLA-4/B7–1) and PD-1 (PD-1/PD-L1) act as brakes for further activation of T cells. CTLA-4 mediates its inhibitory function via endocytosis after binding with its ligand B7–1. The trans interaction of PD-L1 and B7–1 was previously reported to inhibit T cell activation. D) The cis interaction of PD-L1 and B7–1 on both APC and T cells. In co-culture of T cell and APC, the cis interaction of PD-L1 and B7–1 blocks the trans interaction of PD-L1/PD-1, thus making PD-L1 less available on APC for binding PD-1 on T cells, resulting in improved T cell activation. However, this relies on more expression of B7–1 than PD-L1 on APC cells. Interestingly, the cis interaction of PD-L1/B7–1 has no effects on the trans B7–1 binding to CTLA-4 and CD28. E) When PD-L1 outnumbers B7–1 on APC cells, the cis interaction of PD-L1 and B7–1 might have limited effects on trans interaction of PD-L1/PD-1. The excess of PD-L1 on APC could still bind to PD-1 and transmit inhibitory signals to T cells. F) When PD-L1 outnumbers B7–1 on APC cells, blocking cis interaction of PD-L1/B7–1 and trans interaction of PD-L1/PD-1 by anti-PD-L1 can further activate T cells. However, in this case, the released B7–1 on APC might bind to CTLA-4 on T cells and cause their inhibition. Thus, combination of anti-PD-L1 and anti-CTLA-4 under these conditions could maximize T cell activation and may be an efficient approach to improve tumor immunotherapy.CC BY · PubMed Central
Figure 2. PD-1 signaling and interactors. A) T cell activation requires first signal from the TCR by engagement with peptide-loaded MHC. The recruited Src-family kinases, Lck and Fyn by TCR signaling rapidly phosphorylate ITIM and ITSM tyrosines of the cytoplasmic tail of PD-1 (pPD-1). Both SHP-2 and SHP-1 could be recruited to pPD-1, and promote downstream inhibitory signaling. These phosphatases can counteract positive signaling from TCR and CD28, which includes inhibition of ZAP70, SLP-76, protein kinase C (PKC-θ), phosphatidylinositol-3-kinase (PI3K), and the Ras signaling pathway. B) The self-inhibitory structure of SHP-2 binds to pITIM and pTISM of PD-1. SHP-2 contains two SH2 domains, N-terminal (N-SH2) and C-terminal (C-SH2), followed by a PTP domain. After C-SH2 binds to pITSM domain of PD-1, N-SH2 is released from the autoinhibitory conformation and binds to pITIM tyrosine of PD-1. By using a synthetic peptide (GST-PD-1 cytoplasmic tail) as bait to affinity purify candidate proteins in activated human T cells, signaling lymphocytic activation molecule-associated protein (SAP) was discovered in the PD-1 interactome. SAP blocked PD-1 inhibitory functions in T cells through indirect inhibition of SHP-2 activity. SAP did not show direct association with SHP-2 and might interact through a still unknown adaptor protein to inhibit PD-1 signaling. C) SHP-2 outcompetes SHP-1 for binding to phosphorylated PD-1 under physiologic conditions and inhibits both TCR and CD28 signaling. In the absence of SHP-1, SHP-2 could still inhibit T cell activation by downregulation of pSLP76, pLAT, pCD28, and expression of CD69. Interestingly, SHP-1 could mediate PD-1 inhibitory signaling in the absence of SHP-2. Double deletion of SHP-1 and SHP-2 on T cells showed complete loss of PD-1-mediated inhibition of CD28 and TCR signaling. D) Since pITSM of PD-1 could bind to N-SH2 domain of SHP-2, SHP-2 could bridge two pITSM motifs of PD-1 molecules through its N-SH2 and C-SH2 domains, which leads to dimerization of PD-1. In this model, the increased PTP activity of SHP-2 may inhibit TCR or/and CD28 signaling.
Figure 2. PD-1 signaling and interactors. A) T cell activation requires first signal from the TCR by engagement with peptide-loaded MHC. The recruited Src-family kinases, Lck and Fyn by TCR signaling rapidly phosphorylate ITIM and ITSM tyrosines of the cytoplasmic tail of PD-1 (pPD-1). Both SHP-2 and SHP-1 could be recruited to pPD-1, and promote downstream inhibitory signaling. These phosphatases can counteract positive signaling from TCR and CD28, which includes inhibition of ZAP70, SLP-76, protein kinase C (PKC-θ), phosphatidylinositol-3-kinase (PI3K), and the Ras signaling pathway. B) The self-inhibitory structure of SHP-2 binds to pITIM and pTISM of PD-1. SHP-2 contains two SH2 domains, N-terminal (N-SH2) and C-terminal (C-SH2), followed by a PTP domain. After C-SH2 binds to pITSM domain of PD-1, N-SH2 is released from the autoinhibitory conformation and binds to pITIM tyrosine of PD-1. By using a synthetic peptide (GST-PD-1 cytoplasmic tail) as bait to affinity purify candidate proteins in activated human T cells, signaling lymphocytic activation molecule-associated protein (SAP) was discovered in the PD-1 interactome. SAP blocked PD-1 inhibitory functions in T cells through indirect inhibition of SHP-2 activity. SAP did not show direct association with SHP-2 and might interact through a still unknown adaptor protein to inhibit PD-1 signaling. C) SHP-2 outcompetes SHP-1 for binding to phosphorylated PD-1 under physiologic conditions and inhibits both TCR and CD28 signaling. In the absence of SHP-1, SHP-2 could still inhibit T cell activation by downregulation of pSLP76, pLAT, pCD28, and expression of CD69. Interestingly, SHP-1 could mediate PD-1 inhibitory signaling in the absence of SHP-2. Double deletion of SHP-1 and SHP-2 on T cells showed complete loss of PD-1-mediated inhibition of CD28 and TCR signaling. D) Since pITSM of PD-1 could bind to N-SH2 domain of SHP-2, SHP-2 could bridge two pITSM motifs of PD-1 molecules through its N-SH2 and C-SH2 domains, which leads to dimerization of PD-1. In this model, the increased PTP activity of SHP-2 may inhibit TCR or/and CD28 signaling.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. 10.1093/intimm/8.5.765 · DOI · Paper page

Cited by

See all 39

Metadata

Authors
Wang, Q., Bardhan, K., Boussiotis, V. A., & Patsoukis, N.
Affiliations
Beth Israel Deaconess Medical Center (US)
Corresponding author
  • Boussiotis, Vassiliki A.
  • Patsoukis, Nikolaos
Venue
Advanced Biology
Publisher
Wiley
Published
2021-06-25
Volume
5
Issue
9
Pages
e2100758-e2100758
ISSN
2701-0198 (ISSN-L)
OpenAlex
W3174507556
Cited by
39
References
65
Citations by year
2026: 7 · 2025: 7 · 2024: 7 · 2023: 5 · 2022: 13
FWCI
0.76
Type
journal article
Language
en
Open access
Locations
  • Advanced Biology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion, cc-by-nc-nd)
Funders
National Institutes of Health (R01CA238263, R01CA212605, R01CA229784, R21AR073494)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
Keywords
PD-1, PD-L1, PD-L2, T cell activation, immune checkpoint, cancer immunotherapy, PD-1 inhibitors, PD-1 signaling, peripheral tolerance, T cell receptor signaling, combination immunotherapy
MeSH terms
Humans, Immunotherapy, Ligands, Lymphocyte Activation, T-Lymphocytes, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.